Rezolute Inc
RZLT5.852USD
-0.018-0.31%
交易中 （美东）报价延迟15分钟
354.29M总市值
亏损市盈率 TTM
关于 Rezolute Inc 公司
Rezolute, Inc. 是一家后期罕见病公司，专注于改善因高胰岛素血症 (HI) 引起的低血糖症患者的治疗效果。其主要临床资产 Ersodetug（原名 RZ358）是一种潜在的治疗由多种形式的高胰岛素血症引起的低血糖症的方法，包括先天性 HI 和肿瘤性 HI。Ersodetug 是一种静脉注射的人类单克隆抗体，可与胰岛素靶组织（例如肝脏、脂肪和肌肉）中胰岛素受体上的独特位点（变构）结合。先天性是一种罕见的儿科遗传性疾病，其特征是胰腺过量产生胰岛素。RZ402 是一种口服血浆激肽释放酶抑制剂 (PKI)，正在开发作为糖尿病性黄斑水肿 (DME) 慢性治疗的潜在疗法。DME 是糖尿病的血管并发症，也是失明的主要原因。RZ402 旨在阻止缓激肽的产生及其对血管渗漏和炎症的影响。
公司简介
公司代码RZLT
公司名称Rezolute Inc
上市日期Dec 23, 2011
CEOMr. Nevan Charles Elam, J.D.
员工数量59
证券类型Ordinary Share
年结日Dec 23
公司地址275 Shoreline Drive, Suite 500
城市REDWOOD CITY
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编94065
电话16502064507
网址https://www.rezolutebio.com/
公司代码RZLT
上市日期Dec 23, 2011
CEOMr. Nevan Charles Elam, J.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Young-Jin Kim
Mr. Young-Jin Kim
Director
Director
149.95K
+6.39%
Dr. Wladimir Hogenhuis, M.D.
Dr. Wladimir Hogenhuis, M.D.
Independent Director
Independent Director
93.03K
+10.71%
Dr. Nerissa C. Kreher, M.D.
Dr. Nerissa C. Kreher, M.D.
Independent Director
Independent Director
37.58K
+47.36%
Mr. Philippe Fauchet
Mr. Philippe Fauchet
Independent Director
Independent Director
34.50K
+35.29%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Acting Chairman of the Board, Chief Executive Officer
Acting Chairman of the Board, Chief Executive Officer
--
--
Mr. Daron Evans
Mr. Daron Evans
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Gilbert M. (Gil) Labrucherie, J.D.
Mr. Gilbert M. (Gil) Labrucherie, J.D.
Independent Director
Independent Director
--
--
Dr. Brian K. Roberts, M.D.
Dr. Brian K. Roberts, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Erik Harris
Mr. Erik Harris
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Young-Jin Kim
Mr. Young-Jin Kim
Director
Director
149.95K
+6.39%
Dr. Wladimir Hogenhuis, M.D.
Dr. Wladimir Hogenhuis, M.D.
Independent Director
Independent Director
93.03K
+10.71%
Dr. Nerissa C. Kreher, M.D.
Dr. Nerissa C. Kreher, M.D.
Independent Director
Independent Director
37.58K
+47.36%
Mr. Philippe Fauchet
Mr. Philippe Fauchet
Independent Director
Independent Director
34.50K
+35.29%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Acting Chairman of the Board, Chief Executive Officer
Acting Chairman of the Board, Chief Executive Officer
--
--
Mr. Daron Evans
Mr. Daron Evans
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Federated Hermes Global Investment Management Corp.
12.99%
Handok Inc
8.29%
Fidelity Management & Research Company LLC
7.24%
The Vanguard Group, Inc.
2.74%
Vivo Capital, LLC
2.43%
Other
66.31%
持股股东
持股股东
占比
Federated Hermes Global Investment Management Corp.
12.99%
Handok Inc
8.29%
Fidelity Management & Research Company LLC
7.24%
The Vanguard Group, Inc.
2.74%
Vivo Capital, LLC
2.43%
Other
66.31%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
20.30%
Hedge Fund
14.64%
Investment Advisor
13.13%
Corporation
8.29%
Venture Capital
2.47%
Individual Investor
1.41%
Research Firm
1.34%
Pension Fund
0.16%
Private Equity
0.05%
Other
38.21%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
151
53.63M
61.77%
-9.40M
2025Q1
149
54.85M
64.71%
-11.78M
2024Q4
130
52.42M
86.65%
+2.62M
2024Q3
103
45.09M
85.49%
-8.77M
2024Q2
88
47.89M
96.58%
+4.94M
2024Q1
69
35.39M
87.04%
-8.22M
2023Q4
65
37.08M
93.56%
-2.65M
2023Q3
67
32.22M
86.09%
-5.29M
2023Q2
66
32.97M
88.12%
-2.31M
2023Q1
64
32.97M
87.27%
-2.06M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Federated Hermes Global Investment Management Corp.
11.28M
12.99%
--
--
Mar 31, 2025
Handok Inc
7.19M
8.29%
+1.25M
+21.03%
Oct 07, 2024
Fidelity Management & Research Company LLC
6.29M
7.24%
-72.11K
-1.13%
Mar 31, 2025
The Vanguard Group, Inc.
2.38M
2.74%
+54.37K
+2.34%
Mar 31, 2025
Vivo Capital, LLC
2.11M
2.43%
-685.27K
-24.49%
Mar 31, 2025
Marshall Wace LLP
1.85M
2.13%
+1.00M
+118.85%
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
1.74M
2.01%
--
--
Mar 31, 2025
Affinity Asset Advisors LLC
1.70M
1.96%
+125.00K
+7.94%
Mar 31, 2025
Caxton Associates LP
1.32M
1.52%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.29M
1.49%
-1.57M
-54.81%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ALPS Medical Breakthroughs ETF
0.26%
iShares Micro-Cap ETF
0.07%
iShares Russell 2000 Growth ETF
0.02%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 Value ETF
0%
查看更多
ALPS Medical Breakthroughs ETF
占比0.26%
iShares Micro-Cap ETF
占比0.07%
iShares Russell 2000 Growth ETF
占比0.02%
ProShares Hedge Replication ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
